Scientists have identified a post-transplant drug regime which provides the best outcome for patients with new kidneys.
Researchers from the University of Miami, in collaboration with the American Society of Nephrology, found that, following a multi-year study, the combination of two immunosuppressive drugs led to fewer instances of organ rejection and better health after transplant.
Medication following a transplant is a delicate balancing act as immunosuppressant drugs are essential for the acceptance of the new organ but can result in a weaker immune system, leaving the patient open to greater risk of infection, cancer and other risks.
In a study of 150 kidney transplant patients, the scientists found that using tacrolimus and mycophenolate mofetil (MMF) in combination provided the best long-term benefits and fewest side effects.
"We have been able to prove that the use of low-dose tacrolimus and MMF is safe and provides excellent outcomes over time to renal transplant patients," said Dr Giselle Guerra, lead author of the study.
Product directory
